SCHEMBL6354797

SCHEMBL6354797

Clc1ccc(-c2nnnn2Cc2cccc(Cl)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
P2RX7 Q99572 7/20 0.63
ALDH1A1 P00352 1/20 0.55
MEN1 O00255 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.53
POLB P06746 3/20 0.53
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HSD11B1 P28845 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355877 0.90 P2RX7 (0.76) HTTL3MBTL1P2RX7ALDH1A1MEN1
SCHEMBL6357652 0.89 P2RX7 (0.67) HTTL3MBTL1P2RX7MEN1CYP1A2
SCHEMBL5820209 0.88 P2RX7 (0.72) HTTL3MBTL1P2RX7ALDH1A1KMT2A
SCHEMBL6355077 0.84 HTT (1.00) HTTL3MBTL1P2RX7ALDH1A1CYP1A2
SCHEMBL6358994 0.81 POLB (0.84) HTTL3MBTL1P2RX7MEN1CYP1A2
SCHEMBL6357908 0.78 POLB (0.84) HTTL3MBTL1P2RX7MEN1CYP1A2
SCHEMBL4403732 0.78 P2RX7 (0.81) HTTL3MBTL1P2RX7ALDH1A1KMT2A
SCHEMBL6362432 0.78 POLB (0.74) HTTL3MBTL1P2RX7ALDH1A1MEN1
SCHEMBL6357225 0.76 P2RX7 (0.72) HTTL3MBTL1P2RX7ALDH1A1CYP1A2
SCHEMBL6355416 0.76 PTGER1 (0.54) HTTL3MBTL1P2RX7CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 HTT 761/4885L3MBTL1 2120/4885P2RX7 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.